ABVX:EPA
Abivax SA
€76.55
arrow_upward
+1.39%(+1.05) 1D
Nov 18, 4:23:36 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
€75.50
High
€76.90
Low
€75.10
Mkt. cap
6.70B
Avg. vol.
109.70K
Volume
30.71K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
Open
€75.50
High
€76.90
Low
€75.10
Mkt. cap
6.70B
Avg. vol.
109.70K
Volume
30.71K
52-wk high
€139.00
52-wk low
€60.45
EPS
-€5.20
Shares outstanding
87.55M
No. of employees
98
News stories
From web sources and news partners
San Luis Obispo Tribune
·
56 minutes ago
S&P 500, Nasdaq open higher as Nvidia forecast eases AI jitters
Coinpaper
·
45 minutes ago
Dow Jones: Wall Street Eyes Rebound as Morgan Stanley Targets S&P 500 at 8,700
Yahoo Finance
·
1 hour ago
Investors Love the S&P 500 Index. Here’s Why I Don’t.
FOREX.com
·
3 hours ago
S&P 500 Quietly Shrugs Off the Bitcoin and Silver Selloff
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com